Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2009-N-0254]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) has determined that the 19 drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
 FOR FURTHER INFORMATION CONTACT: Olivia Pritzlaff, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6308, Silver Spring, MD 20993-0002, 301-796-3601.


SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. Sponsors of ANDAs do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug. The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is generally known as the “Orange Book.” Under FDA regulations, a drug is withdrawn from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162). Under § 314.161(a) (21 CFR 314.161(a)), the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved; (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved; and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for reasons of safety or effectiveness, the agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug. FDA has become aware that the drug products listed in the table in this document are no longer being marketed. (As requested by the applicants, FDA withdrew approval of NDA 20-225 for IMDUR (isosorbide mononitrate) Extended-Release Tablets in the 
                    **Federal Register**
                     of February 11, 2009 (74 FR 6896) and NDA 11-556 for ANTURANE (sulfinpyrazone) Tablets and Capsules, NDA 15-500 for TOLINASE (tolazamide) Tablets, NDA 18-285 for VISKEN (pindolol) Tablets, NDA 20-137 for DEMADEX (torsemide) Injection, and NDA 20-154 for VIDEX (didanosine) Chewable Tablets in the 
                    **Federal Register**
                     of May 19, 2009 (74 FR 23407)). Application No.
Drug
ApplicantNDA 9-149
THORAZINE (chlorpromazine hydrochloride (HCI)) Injection, 25 milligrams (mg)/milliliter (mL)
GlaxoSmithKline, 2301 Renaissance Blvd., King of Prussia, PA 19406NDA 9-149
THORAZINE (chlorpromazine HCl) Oral Concentrate, 30 mg/mL and 100 mg/mL
Do.NDA 9-149
THORAZINE (chlorpromazine HCl) Oral Syrup, 10 mg/5 mL
Do.NDA 9-149
THORAZINE (chlorpromazine) Suppositories, 25 mg and 100 mg
Do.NDA 11-552
STELAZINE (trifluoperazine HCl) Tablets, Equivalent to (EQ) 1 mg base, EQ 2 mg base, EQ 5 mg base, and EQ 10 mg base
Do.NDA 11-556
ANTURANE (sulfinpyrazone) Tablet, 100 mg
Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07963NDA 11-556
ANTURANE (sulfinpyrazone) Capsule, 200 mg
Do.NDA 12-940
ISORDIL (isosorbide dinitrate) Sublingual Tablets, 2.5 mg, 5 mg, and 10 mg
Biovail Pharmaceuticals, Inc., 700 Route 202-206 North, Bridgewater, NJ 08807-0980NDA 15-500
TOLINASE (tolazamide) Tablets, 100 mg, 250 mg, and 500 mg
Pfifzer, Inc., 235 East 42d St., New York, NY 10017( print page 28256)NDA 18-154
LONITEN (minoxidil) Tablets, 2.5 mg and 10 mg
Pharmacia & Upjohn Co., c/o Pfizer, Inc.NDA 18-285
VISKEN (pindolol) Tablets, 5 mg and 10 mg
Novartis Pharmaceuticals Corp.NDA 18-445
DOLOBID (diflunisal) Tablets, 250 mg and 500 mg
Merck & Co., Inc., Sunneytown Pike, P.O. Box 4, BLA-20, West Point, PA 19486NDA 19-661
CYTOVENE IV (ganciclovir sodium) Injection, EQ 500 mg base/vial
Roche Laboratories, Inc., 340 Kingsland St., Nutley, NJ 07110-1199NDA 20-027
CARDIZEM (diltiazem HCl) Injection, 5 mg/mL and 25 mg/vial
Biovail Pharmaecuticals, Inc.NDA 20-137
DEMADEX (torsemide) Injection, 20 mg/2 mL (10 mg/mL) and 50 mg/5 mL (10 mg/mL)
Roche Laboratories, Inc.NDA 20-154
VIDEX (didanosine) Chewable Tablets, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg
Bristol-Myers Squibb Co., P.O. Box 5100, Wallingford, CT 06492-7660NDA 20-225
IMDUR (isosorbide mononitrate) Extended-Release Tablets, 30 mg, 60 mg, and 120 mg
Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033NDA 21-238
KYTRIL (granisetron HCl) Oral Solution, EQ 2 mg base/10 mL
Roche Laboratories, Inc.NDA 21-301
LEVOXYL (levothyroxine sodium) Tablet, 0.3 mg
King Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN 37620
 FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will continue to list the drug products listed in this document in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. Approved ANDAs that refer to the NDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs. Additional ANDAs that refer to these products may also be approved by the agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the agency will advise ANDA applicants to submit such labeling. Dated: June 5, 2009. Jeffrey Shuren, Associate Commissioner for Policy and Planning.


[FR Doc. E9-14000 Filed 6-12-09; 8:45 am] BILLING CODE 4160-01-S